Story perspectives

ALZ-801 Shows Promise in Slowing Alzheimer's Progression

10/27/2025

27 6

Summary

Story summary

A Phase 3 trial published in Drugs shows valiltramiprosate (ALZ-801) slowed brain atrophy and improved cognitive function in APOE4/4 patients with mild cognitive impairment or mild Alzheimer's dementia.
The trial enrolled 325 participants aged 50 to 80.
The study is notable for focusing on the APOE4/4 high-risk genetic group.
Dr. Susan Abushakra stated that ALZ-801 targets early disease stages and may avoid side effects associated with current treatments.

1 of 1

Story summary

A Phase 3 trial published in Drugs shows valiltramiprosate (ALZ-801) slowed brain atrophy and improved cognitive function in APOE4/4 patients with mild cognitive impairment or mild Alzheimer's dementia.
The trial enrolled 325 participants aged 50 to 80.
The study is notable for focusing on the APOE4/4 high-risk genetic group.
Dr. Susan Abushakra stated that ALZ-801 targets early disease stages and may avoid side effects associated with current treatments.